Next Investors logo grey

New orders further support Creso Pharma’s 700% share price gain


Published 09-DEC-2020 09:29 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Creso Pharma Limited (ASX: CPH; FRA: 1X8) continues to build on a fortnight of strong news flow with its wholly-owned Canadian subsidiary, Mernova Medicinal Inc. receiving three purchase orders with a combined value of C$275,023 (A$288,159).

Further to this was the receipt of a Notice to Purchase from the Province of Ontario, marking the company’s entry into Canada’s largest recreational cannabis market.

The first purchase order valued at C$232,826 (A$243,841) is from Truro Cannabis Company, a licensed producer of medical and recreational cannabis products.

Such has been the quality of the news flow that CPH's shares closed at a 12 month high of 23.5 cents yesterday, up 700% from 3.1 cents a fortnight ago.

Positive company-specific and industry news has underpinned the sharp share price gain, including significant developments on the regulatory front that are likely to benefit Creso Pharma across key markets such as the US and the European Union.

It is worth noting that in the next week it will be Australia’s turn to release important regulatory news regarding its potential rerating of medicinal CBD as an over-the-counter (OTC) product.

Read: Changes to OTC cannabis sales just around the corner

Creso Pharma’s premium products gaining recognition

The Truro order is a bulk order for three of Mernova’s high quality, indoor grown, hand trimmed, hang dried, cured, artisanal cannabis strains, in dried flower form, specifically HPG13, Lemon Haze and Mimosa.

The group has an established presence across Canada, and will sell Mernova’s products through their well-established distribution channels.

Creso Pharma also received a maiden purchase order from the Yukon Liquor Corporation (‘Yukon’), opening a new Canadian market with the company anticipating further orders in the future.

The purchase order for the HPG13, Lemon Haze and Mimosa strains, in dried flower form is valued at C$24,333 (A$25,436).

These products will be sold under the Ritual Green brand in 3.5 gram and 7 gram units, through leading retailer Triple J’s Canna Space.

28a - cph.PNG

These developments serve as confirmation of the significant demand for Mernova’s high-quality cannabis products in the rapidly growing Canadian retail recreational market.

Next Investors Image

Commenting on these recent developments and expressing his confidence regarding the likelihood of further strong order flow, Mernova managing director Jack Yu said, “Mernova continues to make very strong progress in the Canadian recreational market.

‘’The three most recently secured purchase orders will contribute to Creso Pharma’s growing revenue profile and we expect additional orders to materialise in the very near term.

“Mernova has now become part of a very select group of licensed producers with cannabis products for sale in the Yukon.

‘’This is a major achievement for us, and we expect growth to continue across Canada and, with our pending entry into Ontario, Canada’s largest recreational market, we expect rapid growth to continue.”

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.